Update! Watching!
$PepGen (PEPG.US)$ promising data from their 5mg/Kg dose level cohort, which is expected to be shared in mid-2024. This data suggests a high dystrophin expression, which is a strong indicator of PGN-EDO51’s effectiveness. In a head-to-head comparison with SRP-5051, PGN-EDO51 showed a 13-fold increase in exon skipping. Additionally, PepGen’s PGN-EDODM1 has shown promising early results, with significant correction of mis-splicing and myotonia after a single dose, and a tolerability profile that speaks to the company’s work in refining the EDO platform![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
